@SportsLawDude@WVUBaseball West Virginia is still an ass backwards shit hole. Cal Poly comes back to the beach, wineries and hot cali girls. Go eat another potato skin fatty!
@spontonic They pre reported earnings earlier in the year. The # was already out. Problem is SG&A is off the charts. No fiscal discipline. Building out a sales force is dumb. Every NPC physician can use AI for latest treatment guidelines.
$CHRS Ground Hog Day. Another bullshit move by Denny to stroke his ego. There is a not a damn physician in the US that wouldn’t use AI to search most up to date data or recommendations for NPC. It’s 2026 dumbass. Why do you need a sales force?
$CHRS 8-K was telling today. Sales ramp is slow. On the last call they told the market they would be increasing sales head count and filed a shelf registration. Burn rate will be off the chart as the CEO thinks a commercial team for 1 drug is being strategic. Crazy!
$CHRS S-3 Shelf Registration to sell up to $150m. WTF. Get rid of your commercial operations, out license TORI for NPC and develop 114 and Il-27 in house.
@MarcusJone53121 If this were to happen, Coherus would only exist as a distributor of Tori and not a drug development biotech. They would have to sell in both scenarios
$CHRS If CCR8 or IL-27 molecules ever make it to a PMA submission, Coherus would be taken out through an
acquisition, they will never commercialize, so WTF do they have a sales force for Tori in NPC?
$CHRS Should eliminate their commercial team and out license Tori to a Pharma Co calling on these prescribers. Spending $10 to get $1 in revenue is another reason to fire Lanfear
$CHRS. Lanfear's decision to expand the commercial sales team is a horrible decision. Single marketed drug with a small number of patients that has been included in treatment guidelines. Educating physicians through sales calls and lunches is expensive and inefficient.
$CHRS You immediately add Tori to Pfizer's bag, get rid of the commercial team at Coherus. Build the Tori brand as you wait for FDA approval for combo bladder cancer drug which a large market
$CHRS With the new Toripalimab bladder cancer data in combo with Pfizers experimental drug- Why would Pfizer not look to takeout Coherus. You get Tori, CCR8 and Il-27.